Business
Polaryx Therapeutics Welcomes New Members of the Board of Directors
PARAMUS, NJ, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX) a clinical-stage biotechnology company dedicated to the discovery,
About this update from Polaryx Therapeutics, Inc.
[{"type":"text","content":"PARAMUS, NJ, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX) a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), today announces the appointments of Mitchel Berger, M.D., Francis A. Braun III, CPA, and Charles Ryan, J.D., Ph.D. to Polaryx’s Board of Directors, effective January 29, 2026. In addition, Andrew O ceased serving as a member of the Board effective on the same date. Polaryx believes the addition of Dr. Berger, Mr. Braun, and Dr. Ryan brings valuable expertise across scientific research, clinical development, finance, and corporate strategy, strengthening the Board as Polaryx advances as a public company. These appointments come at a pivotal time for Polaryx, as its lead candidate, PLX-200, advances into an IND-approved SOTERIA Phase 2 basket trial, representing a key near-term milestone. “We are truly honored to welcome Dr. Berger, Mr. Braun, and Dr. Ryan to Polaryx’s Board of Directors at this pivotal moment as we achieve a successful listing on Nasdaq,” said Alex Yang, Chairman and Chief Executive Officer, Polaryx Therapeutics, Inc. “As we move forward as a listed company, we believe their collective expertise across multiple aspects of company development will bring tremendous value to Polaryx. We thank Andrew for his valuable contributions during his tenure on the board.” Polaryx’s Lead Independent Director, Dr. Ryan commented, “I am pleased to join Polaryx as a member of the Board of Directors as the Company embarks on its next chapter. Polaryx is uniquely positioned to transform the treatment of rare, pediatric lysosomal storage disorders, and I look forward to supporting the team in achieving its next milestones.” The new Board members are as follows: Mitchel Berger, M.D. is the Director of the Brain Tumor Center at the University of California, San Francisco (UCSF), a position he has held since 1997, and serves as the Principal Investigator of the UCSF Brain Tumor Center’s Specialized Program of Research Excellence (SPORE) in neuro-oncology, funded by the National Cancer Institute. From 1997 to 2020, Dr. Berger served as the Chair of UCSF’s Department of Neurological Surgery. During his career, Dr. Berger has served as President of the Amer...